display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wild
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib IMspire-170
atezolizumab plus SoC IMspire-150 ...
nivolumab based treatment
nivolumab alone CheckMate 067 ... CheckMate 066
nivolumab followed by ipilimumab CheckMate 064

Study type: